Literature DB >> 20496046

Patient and family experiences and opinions on adding 22q11 deletion syndrome to the newborn screen.

Abigail M Bales1, Christina A Zaleski, Elizabeth W McPherson.   

Abstract

22q11 deletion syndrome (22qDS) has recently been proposed for addition to the newborn screening panel in Wisconsin and it seems likely that it may soon be considered in other states as well. Input from patients with 22qDS and their family was gathered from 21 phone interviews. Cardiac, palate, hypocalcemia, and multiple anomalies were common reasons for involved patients to be diagnosed, though age at diagnosis ranged from birth to adulthood. Many commented on their struggles with 22qDS, including worries about the future and the patient's independence. In general, respondents favored newborn screening for 22qDS because it would help prevent some medical problems, increase access to services, explain existing problems, and identify mild cases. However, a minority expressed reservations, including concerns that it would disrupt bonding, could be too costly, and would not be useful for mild cases.

Entities:  

Mesh:

Year:  2010        PMID: 20496046     DOI: 10.1007/s10897-010-9306-0

Source DB:  PubMed          Journal:  J Genet Couns        ISSN: 1059-7700            Impact factor:   2.537


  7 in total

1.  Newborn screening for Duchenne muscular dystrophy: a psychosocial study.

Authors:  E P Parsons; A J Clarke; K Hood; E Lycett; D M Bradley
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2002-03       Impact factor: 5.747

2.  Psychosocial risk associated with newborn screening for cystic fibrosis: parents' experience while awaiting the sweat-test appointment.

Authors:  Audrey Tluczek; Rebecca L Koscik; Philip M Farrell; Michael J Rock
Journal:  Pediatrics       Date:  2005-06       Impact factor: 7.124

3.  Presenting phenotype in 100 children with the 22q11 deletion syndrome.

Authors:  Sólveig Oskarsdóttir; Christina Persson; Bengt O Eriksson; Anders Fasth
Journal:  Eur J Pediatr       Date:  2004-11-23       Impact factor: 3.183

4.  Living with a child at risk for psychotic illness: the experience of parents coping with 22q11 deletion syndrome: an exploratory study.

Authors:  Laura Hercher; Georgette Bruenner
Journal:  Am J Med Genet A       Date:  2008-09-15       Impact factor: 2.802

5.  Newborn screening for mucopolysaccharidoses: opinions of patients and their families.

Authors:  I M Hayes; V Collins; M Sahhar; J E Wraith; M B Delatycki
Journal:  Clin Genet       Date:  2007-05       Impact factor: 4.438

6.  Effect of expanded newborn screening for biochemical genetic disorders on child outcomes and parental stress.

Authors:  Susan E Waisbren; Simone Albers; Steve Amato; Mary Ampola; Thomas G Brewster; Laurie Demmer; Roger B Eaton; Robert Greenstein; Mark Korson; Cecilia Larson; Deborah Marsden; Michael Msall; Edwin W Naylor; Siegfried Pueschel; Margretta Seashore; Vivian E Shih; Harvey L Levy
Journal:  JAMA       Date:  2003-11-19       Impact factor: 56.272

Review 7.  Newborn screening programs: should 22q11 deletion syndrome be added?

Authors:  Abigail M Bales; Christina A Zaleski; Elizabeth W McPherson
Journal:  Genet Med       Date:  2010-03       Impact factor: 8.822

  7 in total
  7 in total

1.  Assessment of parental disclosure of a 22q11.2 deletion syndrome diagnosis and implications for clinicians.

Authors:  Dana Faux; Kelly Schoch; Sonja Eubanks; Stephen R Hooper; Vandana Shashi
Journal:  J Genet Couns       Date:  2012-08-31       Impact factor: 2.537

2.  Elucidating the diagnostic odyssey of 22q11.2 deletion syndrome.

Authors:  Lisa D Palmer; Nancy J Butcher; Erik Boot; Kathleen A Hodgkinson; Tracy Heung; Eva W C Chow; Alina Guna; T Blaine Crowley; Elaine Zackai; Donna M McDonald-McGinn; Anne S Bassett
Journal:  Am J Med Genet A       Date:  2018-04       Impact factor: 2.802

3.  Identification of 22q11.2 Deletion Syndrome via Newborn Screening for Severe Combined Immunodeficiency.

Authors:  Jessica C Barry; Terrence Blaine Crowley; Soma Jyonouchi; Jennifer Heimall; Elaine H Zackai; Kathleen E Sullivan; Donna M McDonald-McGinn
Journal:  J Clin Immunol       Date:  2017-05-24       Impact factor: 8.317

4.  Medical, welfare, and educational challenges and psychological distress in parents caring for an individual with 22q11.2 deletion syndrome: A cross-sectional survey in Japan.

Authors:  Ryo Morishima; Yousuke Kumakura; Satoshi Usami; Akiko Kanehara; Miho Tanaka; Noriko Okochi; Naomi Nakajima; Junko Hamada; Tomoko Ogawa; Shuntaro Ando; Hidetaka Tamune; Mutsumi Nakahara; Seiichiro Jinde; Yukiko Kano; Kyoko Tanaka; Yoichiro Hirata; Akira Oka; Kiyoto Kasai
Journal:  Am J Med Genet A       Date:  2021-09-03       Impact factor: 2.578

5.  MALDI-TOF-MS Assay to Detect the Hemizygous 22q11.2 Deletion in DNA from Dried Blood Spots.

Authors:  Lisa J Kobrynski; Golriz K Yazdanpanah; Deborah Koontz; Francis K Lee; Robert F Vogt
Journal:  Clin Chem       Date:  2015-11-19       Impact factor: 8.327

6.  The psychosocial impact of 22q11 deletion syndrome on patients and families: A systematic review.

Authors:  Oanh Kieu Vo; Alisdair McNeill; Katharina Sophie Vogt
Journal:  Am J Med Genet A       Date:  2018-03-25       Impact factor: 2.802

7.  Discussing the psychiatric manifestations of 22q11.2 deletion syndrome: an exploration of clinical practice among medical geneticists.

Authors:  Emily Morris; Angela Inglis; Jan Friedman; Jehannine Austin
Journal:  Genet Med       Date:  2013-04-11       Impact factor: 8.822

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.